Iovance Biotherapeutics Inc (NAS:IOVA)
$ 8.01 0.04 (0.5%) Market Cap: 2.24 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 40/100

Iovance Biotherapeutics Inc at Cowen Immuno-Oncology Next Summit (Virtual) Transcript

Nov 15, 2021 / 08:45PM GMT
Release Date Price: $19.59 (-7.02%)
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

The next company at our conference is Iovance Biotherapeutics. And it's my pleasure to host Fred, the Interim CEO; and Friedrich, the Chief Medical Officer. Thanks both of you for joining us.

Frederick G. Vogt
Iovance Biotherapeutics, Inc. - Interim President, CEO, General Counsel & Corporate Secretary

Thanks, Boris.

Questions & Answers

Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So I'd like to discuss the issue that I think is at the top of all investors' mind, and that's the regulatory assay. Can you just walk us through the assay development issues that arose during the regulatory review and kind of what stage of validation work you currently are in for this assay?

Frederick G. Vogt
Iovance Biotherapeutics, Inc. - Interim President, CEO, General Counsel & Corporate Secretary

Sure. So during the prior regulatory

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot